This provides proof-of-concept that postnatal therapeutic targeting of Shn3 is able to reverse the osteopenia seen in the Col1a2oim/oim mice and provides specific demonstration of an AAV-based gene therapy approach to Shn3 targeting. The gene discussed is HIVEP3; the disease is Osteopenia.